Commitments and Contingencies (Details) |
12 Months Ended | |||||
|---|---|---|---|---|---|---|
|
May 09, 2025
CHF (SFr)
|
Oct. 10, 2024
USD ($)
|
Oct. 09, 2024
USD ($)
|
Oct. 07, 2024
USD ($)
|
Dec. 31, 2024
USD ($)
|
Dec. 01, 2023
USD ($)
|
|
| Commitments and Contingencies [Line Items] | ||||||
| License consideration paid | $ 250,000 | |||||
| Milestone payments due, description | (i) $750,000 payable following the end of a Phase II meeting with the FDA, with the amount to be reduced to $375,000 if toxicology studies must be repeated; (ii) $2 million following the earlier of U.S. Food and Drug Administration (“FDA”) marketing authorization of Quilience or Nolazol; (iii) 1% of any upfront and milestone payments, if any, from any sublicensees and (iv) $3 million as a one-time payment upon the Company’s product candidate reaching $250 million in cumulative sales. | |||||
| Aggregate amount | $ 200,013 | $ 492,723 | ||||
| Unpaid interest | $ 110,179 | $ 886,412 | ||||
| Interest rate, percentage | 5.00% | 6.00% | ||||
| Dunn Lambert LLC [Member] | ||||||
| Commitments and Contingencies [Line Items] | ||||||
| Aggregate amount | 279,300 | |||||
| CoreRX [Member] | ||||||
| Commitments and Contingencies [Line Items] | ||||||
| Aggregate amount | 511,835 | |||||
| Chad Hellman [Member] | ||||||
| Commitments and Contingencies [Line Items] | ||||||
| Unpaid consulting fees | $ 36,940 | $ 35,171 | ||||
| Maximum [Member] | Dunn Lambert LLC [Member] | ||||||
| Commitments and Contingencies [Line Items] | ||||||
| Unpaid interest | 500,223 | |||||
| Minimum [Member] | Dunn Lambert LLC [Member] | ||||||
| Commitments and Contingencies [Line Items] | ||||||
| Unpaid interest | $ 49,475 | |||||
| Forecast [Member] | ||||||
| Commitments and Contingencies [Line Items] | ||||||
| Unpaid interest | SFr | SFr 30,000 | |||||
| Interest rate, percentage | 5.00% |